Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: Results of a prospective study (ALL MRD2002 Study)

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Nagafuji, Koji ^a   Miyamoto, Toshihiro ^b   Eto, Tetsuya ^c   Kamimura, Tomohiko ^d   Taniguchi, Shuichi ^e   Okamura, Takashi ^a   Ohtsuka, Eiichi ^f   Yoshida, Takashi ^g   Higuchi, Masakazu ^h   Yoshimoto, Goichi ⁱ   Fujisaki, Tomoaki ^j   Abe, Yasunobu ^b   Takamatsu, Yasushi ^k   Yokota, Shouhei ^l   Akashi, Koichi ^b   Harada, Mine ^m  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c HAMANOMACHI HOSPITAL   (Japan)

^d HARASANSHIN HOSPITAL   (Japan)

^e TORANOMON HOSPITAL   (Japan)

^f OITA PREFECTURAL HOSPITAL   (Japan)

^g TOYAMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^h KYUSHU KOSEI NENKIN HOSPITAL   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^j MATSUYAMA RED CROSS HOSPITAL   (Japan)

^k FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^l KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^m Medical Center for Karatsu Higashimatuura Medical Association   (Japan)

more..

Author keywords

Acute lymphoblastic leukemia; Adult; Hematopoietic stem cell transplantation; Minimal residual disease

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; FOLINIC ACID; MESSENGER RNA; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; T LYMPHOCYTE RECEPTOR; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ADULT DISEASE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PHILADELPHIA CHROMOSOME; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84873255438     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-14     Document Type: Article

References (37)

1. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. D Hoelzer, E Thiel, H Loffler, T Buchner, A Ganser, G Heil, P Koch, M Freund, H Diedrich, H Ruhl, Blood 1988 71 123 131 3422030
2. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. H Kantarjian, D Thomas, S O'Brien, J Cortes, F Giles, S Jeha, CE Bueso-Ramos, S Pierce, J Shan, C Koller, et al. Cancer 2004 101 2788 2801 10.1002/cncr.20668 15481055
3. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. JM Rowe, G Buck, AK Burnett, R Chopra, PH Wiernik, SM Richards, HM Lazarus, IM Franklin, MR Litzow, N Ciobanu, et al. Blood 2005 106 3760 3767 10.1182/blood-2005-04-1623 16105981
4. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. HM Lazarus, SM Richards, R Chopra, MR Litzow, AK Burnett, PH Wiernik, IM Franklin, MS Tallman, L Cook, G Buck, et al. Blood 2006 108 465 472 10.1182/blood-2005-11-4666 16556888
5. Initial and late prognostic factors to predict survival in adult acute lymphoblastic leukaemia. QH Le, X Thomas, R Ecochard, J Iwaz, V Lheritier, M Michallet, D Fiere, Eur J Haematol 2006 77 471 479 10.1111/j.1600-0609.2006. 00753.x 16978239
6. Adult acute lymphoblastic leukemia: concepts and strategies. S Faderl, S O'Brien, CH Pui, W Stock, M Wetzler, D Hoelzer, HM Kantarjian, Cancer 2010 116 1165 1176 10.1002/cncr.24862 20101737
7. Allogeneic Hematopoietic Cell Transplantation Is Not Recommended for all Adults with Standard-Risk Acute Lymphoblastic Leukemia in First Complete Remission. RA Larson, Biol Blood Marrow Transplant 2009 15 11 16 19147070
8. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. J Brisco, E Hughes, SH Neoh, PJ Sykes, K Bradstock, A Enno, J Szer, K McCaul, AA Morley, Blood 1996 87 5251 5256 8652840
9. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. FY Mortuza, M Papaioannou, IM Moreira, LA Coyle, P Gameiro, D Gandini, HG Prentice, A Goldstone, AV Hoffbrand, L Foroni, J Clin Oncol 2002 20 1094 1104 10.1200/JCO.20.4.1094 11844835
10. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. M Bruggemann, T Raff, T Flohr, N Gokbuget, M Nakao, J Droese, S Luschen, C Pott, M Ritgen, U Scheuring, et al. Blood 2006 107 1116 1123 16195338
11. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. T Raff, N Gokbuget, S Luschen, R Reutzel, M Ritgen, S Irmer, S Bottcher, HA Horst, M Kneba, D Hoelzer, M Bruggemann, Blood 2007 109 910 915 17023577
12. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. O Spinelli, B Peruta, M Tosi, V Guerini, A Salvi, MC Zanotti, E Oldani, A Grassi, T Intermesoli, C Mico, et al. Haematologica 2007 92 612 618 10.3324/haematol.10965 17488684
13. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). R Bassan, O Spinelli, E Oldani, T Intermesoli, M Tosi, B Peruta, G Rossi, E Borlenghi, EM Pogliani, E Terruzzi, et al. Blood 2009 113 4153 4162 10.1182/blood-2008-11-185132 19141862
14. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. B Patel, L Rai, G Buck, SM Richards, Y Mortuza, W Mitchell, G Gerrard, AV Moorman, V Duke, AV Hoffbrand, et al. Br J Haematol 2009 148 80 89 19863538
15. Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia. SR Cataland, CK Daugherty, EC Weseman, RA Larson, Leuk Lymphoma 2001 41 297 307 10.3109/10428190109057984 11378542
16. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia. W Stock, JL Johnson, RM Stone, JE Kolitz, BL Powell, M Wetzler, P Westervelt, G Marcucci, DJ DeAngelo, JW Vardiman, et al. Cancer 2013 119 90 98 10.1002/cncr.27617 22744771
17. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL positive acute lymphoblastic leukemia. M Towatari, M Yanada, N Usui, J Takeuchi, I Sugiura, M Takeuchi, F Yagasaki, Y Kawai, S Miyawaki, S Ohtake, et al. Blood 2004 104 3507 3512 10.1182/blood-2004-04-1389 15315963
18. Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia. M Kikuchi, J Tanaka, T Kondo, S Hashino, M Kasai, M Kurosawa, H Iwasaki, M Morioka, T Kawamura, N Masauzi, et al. Int J Hematol 2010 92 481 489 10.1007/s12185-010-0670-1 20830615
19. Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. S Yokota, T Hansen-Hagge, W Ludwig, A Reiter, A Raghavachar, E Kleihauer, C Bartram, Blood 1991 77 331 339 1824678
20. Minimal residual disease in early phase of chemotherapy reflects poor outcome in children with acute lymphoblastic leukemia-a retrospective study by the Children's Cancer and Leukemia Study Group in Japan. T Okamoto, S Yokota, N Katano, T Seriu, M Nakao, M Taniwaki, A Watanabe, K Asami, A Kikuta, S Koizumi, et al. Leuk Lymphoma 2002 43 1001 1006 10.1080/10428190290021641 12148878
21. Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group. K Yamaji, T Okamoto, S Yokota, A Watanabe, Y Horikoshi, K Asami, A Kikuta, N Hyakuna, Y Saikawa, J Ueyama, et al. Pediatr Blood Cancer 2010 55 1287 1295 10.1002/pbc.22620 20535816
22. Treatment of acute lymphoblastic leukemia. CH Pui, WE Evans, N Engl J Med 2006 354 166 178 10.1056/NEJMra052603 16407512
23. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). AH Goldstone, SM Richards, HM Lazarus, MS Tallman, G Buck, AK Fielding, AK Burnett, R Chopra, PH Wiernik, L Foroni, et al. Blood 2008 111 1827 1833 10.1182/blood-2007-10- 116582 18048644
24. GIMEMA ALL-Rescue 97: a salvage strategy for primary refractory or relapsed adult acute lymphoblastic leukemia. A Camera, L Annino, F Chiurazzi, P Fazi, N Cascavilla, F Fabbiano, F Marmont, F Di Raimondo, A Recchia, M Vignetti, et al. Haematologica 2004 89 145 153 15003889
25. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. AK Fielding, SM Richards, R Chopra, HM Lazarus, MR Litzow, G Buck, IJ Durrant, SM Luger, DI Marks, IM Franklin, et al. Blood 2007 109 944 950 17032921
26. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. E Tavernier, JM Boiron, F Huguet, K Bradstock, N Vey, T Kovacsovics, A Delannoy, N Fegueux, P Fenaux, A Stamatoullas, et al. Leukemia 2007 21 1907 1914 10.1038/sj.leu.2404824 17611565
27. Chemotherapy vs HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission. H Oh, RP Gale, MJ Zhang, JR Passweg, T Ino, H Murakami, R Ohno, PA Rowlings, KA Sobocinski, M Tanimoto, et al. BMT 1998 22 253 257
28. Chemotherapy or allografting for young adults with high-risk ALL? C Anasetti, Blood 2008 111 5755 18544698
29. Response: Chemotherapy or allografting for young adults with high-risk ALL? AH Goldstone, SM Richards, AK Fielding, JM Rowe, Blood 2008 111 5755 18544698
30. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. E Barry, DJ DeAngelo, D Neuberg, K Stevenson, ML Loh, BL Asselin, RD Barr, LA Clavell, CA Hurwitz, A Moghrabi, et al. J Clin Oncol 2007 25 813 819 10.1200/JCO.2006.08.6397 17327603
31. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. JM Ribera, A Oriol, MA Sanz, M Tormo, P Fernandez-Abellan, E Del Potro, E Abella, J Bueno, R Parody, P Bastida, et al. J Clin Oncol 2008 26 1843 1849 10.1200/JCO.2007.13. 7265 18398150
32. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. W Stock, M La, B Sanford, CD Bloomfield, JW Vardiman, P Gaynon, RA Larson, J Nachman, Children's Cancer G, Cancer, Leukemia Group Bs, Blood 2008 112 1646 1654 10.1182/blood-2008-01-130237 18502832
33. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. F Huguet, T Leguay, E Raffoux, X Thomas, K Beldjord, E Delabesse, P Chevallier, A Buzyn, A Delannoy, Y Chalandon, et al. J Clin Oncol 2009 27 911 918 10.1200/JCO.2008.18.6916 19124805
34. Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults. ES Schafer, SP Hunger, Nat Rev Clin Oncol 2011 8 417 424 10.1038/nrclinonc.2011.77 21629213
35. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. VHJ Van der Velden, DCH Jacobs, AJM Wijkhuijs, WM Comans-Bitter, MJ Willemse, K Hahlen, Leukemia 2002 16 1432 1436 10.1038/sj.leu.2402636 12145681
36. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. VH van der Velden, ER Panzer-Grumayer, G Cazzaniga, T Flohr, R Sutton, A Schrauder, G Basso, M Schrappe, JM Wijkhuijs, M Konrad, et al. Leukemia 2007 21 706 713 17287857
37. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. N Gökbuget, M Kneba, T Raff, H Trautmann, C-R Bartram, R Arnold, R Fietkau, M Freund, A Ganser, W-D Ludwig, et al. Blood 2012 120 1868 1876 10.1182/blood-2011-09-377713 22442346